Clinical Trial Update: A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating paclitaxel with apatinib and adebrelimab in gastric/gastroesophageal junction adenocarcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• Apatinib (apatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING